FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Links shared publicly online about this topic.

1,229
total visits

FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the Company has received U.S. Food and Drug Administration (FDA) approval to market mesna injection (mesna), a prophylactic agent used to reduce the incidence of hemorrhagic cystitis caused by ifosfamide chemotherapy.

View full resource at news-medical.net

Tags: Chemotherapy, Drug, Pharma, FDA